Cargando…

Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer

PURPOSE: We aimed to elucidate the potential mechanisms of effective responsiveness to PD-1 monoclonal antibody and evaluate more reliable biomarkers to improve the ability to predict the populations of cervical cancer (CC) suitable for immunotherapy. METHODS: Peripheral blood samples of CC patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xihan, Zhang, Xi, Liu, Chang, Mu, Wendi, Peng, Jin, Song, Kun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519820/ https://www.ncbi.nlm.nih.gov/pubmed/36171464 http://dx.doi.org/10.1007/s12672-022-00560-8

Ejemplares similares

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy
por: Lu, Dan, et al.
Publicado: (2022)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

Monoclonal antibodies in cervical malignancy-related HPV
por: Aghbash, Parisa Shiri, et al.
Publicado: (2022)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy
por: Liu, Hongchuan, et al.
Publicado: (2019)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Mutant monoclonal antibodies with alterations in biological functions
por: Yelton, DE, et al.
Publicado: (1982)

The FG Loop of PD-1 Serves as a “Hotspot” for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy
por: Chen, Danqing, et al.
Publicado: (2019)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
por: Tan, Shuguang, et al.
Publicado: (2016)

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
por: Mu, Songlin, et al.
Publicado: (2022)

DNA immunization as a technology platform for monoclonal antibody induction
por: Liu, Shuying, et al.
Publicado: (2016)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
por: Choi, Jin Wook, et al.
Publicado: (2020)

High TRIM44 expression as a valuable biomarker for diagnosis and prognosis in cervical cancer
por: Liu, Shuang, et al.
Publicado: (2019)

Monoclonal enolase-1 blocking antibody ameliorates pulmonary inflammation and fibrosis
por: Huang, Wei-Ching, et al.
Publicado: (2023)

Human monoclonal antibodies and monoclonal antibody multispecificity.
por: Campbell, A. M., et al.
Publicado: (1987)

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
por: Zhang, Shuang, et al.
Publicado: (2018)

Five candidate biomarkers associated with the diagnosis and prognosis of cervical cancer
por: Han, Hong-Yan, et al.
Publicado: (2021)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation
por: Wang, Mingzhu, et al.
Publicado: (2019)

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li, Shi-Yan, et al.
Publicado: (2013)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
por: Shibata, Yosuke, et al.
Publicado: (2023)

Colostrum Antibodies, Egg Antibodies and Monoclonal Antibodies Providing Passive Immunity for Animals
por: DuBourdieu, Dan
Publicado: (2019)

Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor
por: Liu, Jingxian, et al.
Publicado: (2019)

Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients
por: Li, Wenbin, et al.
Publicado: (2018)

Amelioration of joint inflammation by a PAR-2-specific monoclonal antibody
por: King, V, et al.
Publicado: (2005)

Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy
por: Liu, Hongchuan, et al.
Publicado: (2020)

Production and characterisation of a monoclonal antibody (Cx-99) against cervical carcinoma.
por: Yuan, C. C., et al.
Publicado: (1992)

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development
por: Phakham, Tanapati, et al.
Publicado: (2022)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
por: Rotman, Jossie, et al.
Publicado: (2020)

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
por: Kambayashi, Yumi, et al.
Publicado: (2019)

Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies
por: Al-Showbaki, Laith, et al.
Publicado: (2022)

From rabbit antibody repertoires to rabbit monoclonal antibodies
por: Weber, Justus, et al.
Publicado: (2017)

Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials
por: Zhu, Peng, et al.
Publicado: (2021)

New mechanisms and biomarkers of lymph node metastasis in cervical cancer: reflections from plasma proteomics
por: Han, Sai, et al.
Publicado: (2023)

The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma
por: Wang, Huiyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jio11v3lhg1054gimi4cqsaj3l